We were hoping to be in Paris for the ESMO Congress 2021, but the event will be virtual for the second consecutive year due to the COVID-19 pandemic.
However, this annual Congress will confirm that cancer research is blooming again, despite the current health crisis and its remarkable consequences on people, healthcare system, and, not the least, research.
In the last years, we witnessed the achievement of multiple significant improvements, in terms of molecular characterization and treatment, in some cancers such as lung cancer, melanoma and breast cancer.
The ESMO Congress 2021 will shed a light on the need for a more comprehensive molecular characterization for all tumour types, with fascinating results on mesothelioma and sarcoma and for patients with carcinoma-of-unknown-primary-origin (CUP). Thanks to the improvement in biomarker discovery and understanding, it is now time to look forward. Indeed, it will be exciting to learn how the use of target agents will improve the efficacy in sarcoma and rare diseases, something that we could not imagine until yesterday.
This will be the Congress of seeing beyond, where immune checkpoint inhibitors find their place in less common diseases, like endocrine and neuroendocrine tumours, as well as gynaecological cancer.
This will also be the Congress of acknowledging immunotherapy in early setting, in particular for lung cancer and melanoma in the adjuvant setting.
And finally, this will be the Congress of eagerly awaited overall survival data in breast cancer, and new promising targets and immune therapeutics in lung cancer.
But above all, this will be the ESMO Congress that you cannot miss. Yet for this, the ESMO Daily Reporter will be here to keep you updated and to open an opportunity to reflect on the latest findings in cancer care with the daily Expert Commentary, a live stream event taking place on 17-21 September and which will be an occasion to get closer to each other, despite the pandemic.
